AUTHORS
Madeline Ashleigh Franke, MD, MEng, Terra Lasho, PhD2, Abhishek Avinash Mangaonkar, MBBS3, Jenna Fernandez, Ph.D.4, Yael Kusne, MD, PhD5, Tariq Kewan, MD6, Olisaemeka Ogbue, MBBS7, Nickolas Steinauer, M.D., Ph.D.8, Talha Badar, MD9, Jodi Rindflesch, RN10, Eva M. Carmona, MD, PhD11, Alejandro Ferrer, PhD12, Mrinal M. Patnaik, MD, MBBS13
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Phoenix, Arizona, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Jacksonville, Florida, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Introduction: Clonal hematopoiesis (CH) arises through the acquisition of somatic mutations in hematopoietic stem and progenitor cells. In contrast to age-related CH, telomere biology disorders (TBDs) are characterized by a unique somatic mosaic landscape enriched for U2AF1 S34 hotspot splicing-factor variants. However, the biological basis for this enrichment and the clinical significance of U2AF1-mutant CH in TBD remain poorly understood. Therefore, we aimed to define the prevalence, clonal architecture, and clinical outcomes associated with U2AF1 variants in patients with TBD.
Methods: After IRB approval, patients with suspected TBD based on family history or clinical phenotype underwent peripheral blood FlowFISH telomere length (TL) testing and genetic screening. Patients were included in the TBD database based on clinical findings (lung/liver disease, bone marrow failure), short lymphocyte TLs (<10th percentile) and a TBD-associated variant (or TL<1st percentile if no variant was identified). Further testing used a customized error corrected sequencing panel covering 52 genes associated with TBD, detecting variants to 0.5% variant allele fraction (VAF) with 10,000x sequencing depth [Ferrer et al., AJH 2023]. We subsequently identified patients with U2AF1 mutations for further analysis. Patients with myeloid neoplasms were excluded.
Results: CH data were available for 68/113 (60%) patients with TBD, of whom 9 (13%) had U2AF1 variants (67% male; median age 57 years [range, 28–74]). Variants clustered at the canonical hotspots S34F/Y (n=8) and Q157P (n=1), with a median U2AF1 VAF of 8% (range, 1.6–30.3%). Germline TBD variants were identified in 7/9 patients (TERT, n=4; RTEL1, n=2; TERC, n=1), and 7/9 had lymphocyte TLs <1st percentile. Pathogenic co-variants were in the promoter TERT region (pTERT) (n=2), RUNX1 (n=2), ASXL1 (n=1), SETBP1 (n=1), TET2 (n=1), ZRSR2 (n=1), PPM1D (n=1), SF3B1 (n=1), DNMT3A (n=1), and CUX1 (n=1).
With a median follow-up of 2 years (range, 1–9), 2 patients (22%) progressed to MDS and none developed AML. Both patients who progressed had multiple pathogenic myeloid co-mutations (ASXL1/CUX1/SETBP1 and RUNX1/ZRSR2), whereas 6 of 7 patients without MDS had ≤1 pathogenic co-mutation. The most indolent clinical courses were observed in patients whose U2AF1 clones were accompanied by isolated DNMT3A or pTERT alterations. Both patients with MDS remained clinically stable and under observation; the first stable for more than 6 years despite expansion of U2AF1, ASXL1, and SETBP1 clones, while the second remains stable after 1 year of follow-up.
Baseline hematologic manifestations at TBD diagnosis included anemia (56%), thrombocytopenia (56%), macrocytosis (78%), hypocellular bone marrow (BM; 56%), and BM failure (56%). Blood counts and BM cellularity remained largely stable at follow-up, although there was some mild progression of anemia and BM hypocellularity. Extra-hematopoietic manifestations included interstitial lung disease (67%), hepatic disease (11%) and solid tumor cancers (44%). Cytogenetic evolution was uncommon, occurring only in two patients (trisomy 8 and +1,der(1;14)).
The only patient with U2AF1 Q157P (VAF 12.3%) also carried RUNX1 (9%) and ZRSR2 (4.4%) co-mutations and progressed to MDS with +1,der(1;14).
Conclusions: U2AF1 CH in TBD follows a distinct context-dependent evolutionary trajectory characterized by enrichment of S34 hotspot mutations. While isolated U2AF1 mutations without high-risk somatic co-mutations appear to be associated with relatively stable CH, progression to MDS occurred only in patients who acquired cooperating pathogenic myeloid mutations. These findings suggest that co-mutation burden, rather than U2AF1 alone, may be associated with maladaptive clonal evolution in TBD.
DISCLOSURES
Madeline Ashleigh Franke, MD, MEng: No relevant conflicts of interest to declare.